Compare GRND & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRND | STOK |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | 148 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 2019 |
| Metric | GRND | STOK |
|---|---|---|
| Price | $12.27 | $33.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $19.67 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 1.2M | 782.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $17.04 | $82.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $9.79 | $5.35 |
| 52 Week High | $25.13 | $40.22 |
| Indicator | GRND | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 50.94 |
| Support Level | $11.83 | $32.70 |
| Resistance Level | $12.90 | $35.63 |
| Average True Range (ATR) | 0.46 | 2.34 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 39.19 | 69.05 |
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.